Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.
Metrics to compare | RVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −1.7x | −0.5x | |
PEG Ratio | −0.08 | −0.04 | 0.00 | |
Price/Book | −0.2x | 3.6x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.3x | |
Upside (Analyst Target) | - | 741.4% | 48.1% | |
Fair Value Upside | Unlock | 16.8% | 7.7% | Unlock |